News and Announcements
Clinical Trial in Dogs is now open for accrual
- Published October 02, 2014 11:28AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
ASX Release; Thursday 02 October 2014
PhamAus Limited (“PharmAust”or “ the Company”) (ASX:PAA& PAAO) is pleased to announce that following reformulation of PPL-1 into “soft-gel” capsules to improve palatability for dogs, the Animal Referral Hospital (ARH) in Homebush NSW, with principal investor Dr Angela Frimberger, announced today initiation of accrual of canine patients. This announcement is intended to alert dog owners with pest diagnosed with cancer that the trial is open for recruitment.
The trial evaluates the drug PPL-1, which has shown promising anti-cancer results in vitro and in mice. Previous safety studies in dogs have shown the drug is extremely well tolerated. The trial has been approved by the Director General’s Animal Care and Ethics Committee for the treatment of dogs with soft tissue sarcomas, melanomas, and lymphomas, using PPL-1 in a “soft-gel” capsule.
To view the full ASX Release, please click here.